nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.00168	0.00168	CcSEcCtD
Oritavancin—Malnutrition—Estradiol—prostate cancer	0.00168	0.00168	CcSEcCtD
Oritavancin—Skin disorder—Goserelin—prostate cancer	0.00168	0.00168	CcSEcCtD
Oritavancin—Tachycardia—Conjugated Estrogens—prostate cancer	0.00168	0.00168	CcSEcCtD
Oritavancin—Urticaria—Ethinyl Estradiol—prostate cancer	0.00167	0.00167	CcSEcCtD
Oritavancin—Infestation NOS—Etoposide—prostate cancer	0.00167	0.00167	CcSEcCtD
Oritavancin—Infestation—Etoposide—prostate cancer	0.00167	0.00167	CcSEcCtD
Oritavancin—Hyperuricaemia—Doxorubicin—prostate cancer	0.00167	0.00167	CcSEcCtD
Oritavancin—Skin disorder—Conjugated Estrogens—prostate cancer	0.00167	0.00167	CcSEcCtD
Oritavancin—Dizziness—Bicalutamide—prostate cancer	0.00165	0.00165	CcSEcCtD
Oritavancin—Blood bilirubin increased—Doxorubicin—prostate cancer	0.00164	0.00164	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Docetaxel—prostate cancer	0.00162	0.00162	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Docetaxel—prostate cancer	0.00159	0.00159	CcSEcCtD
Oritavancin—Vomiting—Bicalutamide—prostate cancer	0.00158	0.00158	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Goserelin—prostate cancer	0.00158	0.00158	CcSEcCtD
Oritavancin—Blood uric acid increased—Doxorubicin—prostate cancer	0.00158	0.00158	CcSEcCtD
Oritavancin—Rash—Bicalutamide—prostate cancer	0.00157	0.00157	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Capecitabine—prostate cancer	0.00157	0.00157	CcSEcCtD
Oritavancin—Dermatitis—Bicalutamide—prostate cancer	0.00157	0.00157	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Conjugated Estrogens—prostate cancer	0.00156	0.00156	CcSEcCtD
Oritavancin—Headache—Bicalutamide—prostate cancer	0.00156	0.00156	CcSEcCtD
Oritavancin—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.00155	0.00155	CcSEcCtD
Oritavancin—Angioedema—Estradiol—prostate cancer	0.00154	0.00154	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Capecitabine—prostate cancer	0.00154	0.00154	CcSEcCtD
Oritavancin—Bronchospasm—Docetaxel—prostate cancer	0.00153	0.00153	CcSEcCtD
Oritavancin—Pruritus—Ethinyl Estradiol—prostate cancer	0.00149	0.00149	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.00148	0.00148	CcSEcCtD
Oritavancin—Bronchospasm—Capecitabine—prostate cancer	0.00148	0.00148	CcSEcCtD
Oritavancin—Nausea—Bicalutamide—prostate cancer	0.00148	0.00148	CcSEcCtD
Oritavancin—Anaemia—Mitoxantrone—prostate cancer	0.00145	0.00145	CcSEcCtD
Oritavancin—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.00144	0.00144	CcSEcCtD
Oritavancin—Myalgia—Estradiol—prostate cancer	0.00143	0.00143	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.00142	0.00142	CcSEcCtD
Oritavancin—Erythema multiforme—Etoposide—prostate cancer	0.00142	0.00142	CcSEcCtD
Oritavancin—Dizziness—Ethinyl Estradiol—prostate cancer	0.00139	0.00139	CcSEcCtD
Oritavancin—Cardiac disorder—Etoposide—prostate cancer	0.00139	0.00139	CcSEcCtD
Oritavancin—Infestation NOS—Docetaxel—prostate cancer	0.00139	0.00139	CcSEcCtD
Oritavancin—Infestation—Docetaxel—prostate cancer	0.00139	0.00139	CcSEcCtD
Oritavancin—Urticaria—Goserelin—prostate cancer	0.00138	0.00138	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Prednisone—prostate cancer	0.00137	0.00137	CcSEcCtD
Oritavancin—Infection—Estradiol—prostate cancer	0.00137	0.00137	CcSEcCtD
Oritavancin—Urticaria—Conjugated Estrogens—prostate cancer	0.00136	0.00136	CcSEcCtD
Oritavancin—Immune system disorder—Etoposide—prostate cancer	0.00135	0.00135	CcSEcCtD
Oritavancin—Mediastinal disorder—Etoposide—prostate cancer	0.00135	0.00135	CcSEcCtD
Oritavancin—Nervous system disorder—Estradiol—prostate cancer	0.00135	0.00135	CcSEcCtD
Oritavancin—Infestation NOS—Capecitabine—prostate cancer	0.00134	0.00134	CcSEcCtD
Oritavancin—Infestation—Capecitabine—prostate cancer	0.00134	0.00134	CcSEcCtD
Oritavancin—Tachycardia—Estradiol—prostate cancer	0.00134	0.00134	CcSEcCtD
Oritavancin—Vomiting—Ethinyl Estradiol—prostate cancer	0.00134	0.00134	CcSEcCtD
Oritavancin—Myalgia—Mitoxantrone—prostate cancer	0.00134	0.00134	CcSEcCtD
Oritavancin—Skin disorder—Estradiol—prostate cancer	0.00134	0.00134	CcSEcCtD
Oritavancin—Rash—Ethinyl Estradiol—prostate cancer	0.00133	0.00133	CcSEcCtD
Oritavancin—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00133	0.00133	CcSEcCtD
Oritavancin—Headache—Ethinyl Estradiol—prostate cancer	0.00132	0.00132	CcSEcCtD
Oritavancin—Hypersensitivity—Goserelin—prostate cancer	0.00128	0.00128	CcSEcCtD
Oritavancin—Infection—Mitoxantrone—prostate cancer	0.00127	0.00127	CcSEcCtD
Oritavancin—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.00127	0.00127	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Estradiol—prostate cancer	0.00125	0.00125	CcSEcCtD
Oritavancin—Nausea—Ethinyl Estradiol—prostate cancer	0.00125	0.00125	CcSEcCtD
Oritavancin—Tachycardia—Mitoxantrone—prostate cancer	0.00125	0.00125	CcSEcCtD
Oritavancin—Hypoglycaemia—Epirubicin—prostate cancer	0.00125	0.00125	CcSEcCtD
Oritavancin—Skin disorder—Mitoxantrone—prostate cancer	0.00124	0.00124	CcSEcCtD
Oritavancin—Oedema peripheral—Docetaxel—prostate cancer	0.00123	0.00123	CcSEcCtD
Oritavancin—Pruritus—Goserelin—prostate cancer	0.00123	0.00123	CcSEcCtD
Oritavancin—Connective tissue disorder—Docetaxel—prostate cancer	0.00122	0.00122	CcSEcCtD
Oritavancin—Pruritus—Conjugated Estrogens—prostate cancer	0.00122	0.00122	CcSEcCtD
Oritavancin—Anaemia—Etoposide—prostate cancer	0.00121	0.00121	CcSEcCtD
Oritavancin—Oedema peripheral—Capecitabine—prostate cancer	0.00119	0.00119	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Estradiol—prostate cancer	0.00119	0.00119	CcSEcCtD
Oritavancin—Diarrhoea—Goserelin—prostate cancer	0.00119	0.00119	CcSEcCtD
Oritavancin—Connective tissue disorder—Capecitabine—prostate cancer	0.00119	0.00119	CcSEcCtD
Oritavancin—Erythema multiforme—Docetaxel—prostate cancer	0.00118	0.00118	CcSEcCtD
Oritavancin—Diarrhoea—Conjugated Estrogens—prostate cancer	0.00118	0.00118	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.00117	0.00117	CcSEcCtD
Oritavancin—Cardiac disorder—Docetaxel—prostate cancer	0.00116	0.00116	CcSEcCtD
Oritavancin—Hypoglycaemia—Doxorubicin—prostate cancer	0.00115	0.00115	CcSEcCtD
Oritavancin—Dizziness—Goserelin—prostate cancer	0.00115	0.00115	CcSEcCtD
Oritavancin—Erythema multiforme—Capecitabine—prostate cancer	0.00114	0.00114	CcSEcCtD
Oritavancin—Dizziness—Conjugated Estrogens—prostate cancer	0.00114	0.00114	CcSEcCtD
Oritavancin—Immune system disorder—Docetaxel—prostate cancer	0.00113	0.00113	CcSEcCtD
Oritavancin—Mediastinal disorder—Docetaxel—prostate cancer	0.00112	0.00112	CcSEcCtD
Oritavancin—Cardiac disorder—Capecitabine—prostate cancer	0.00112	0.00112	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.0011	0.0011	CcSEcCtD
Oritavancin—Vomiting—Goserelin—prostate cancer	0.0011	0.0011	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Epirubicin—prostate cancer	0.00109	0.00109	CcSEcCtD
Oritavancin—Rash—Goserelin—prostate cancer	0.00109	0.00109	CcSEcCtD
Oritavancin—Dermatitis—Goserelin—prostate cancer	0.00109	0.00109	CcSEcCtD
Oritavancin—Vomiting—Conjugated Estrogens—prostate cancer	0.00109	0.00109	CcSEcCtD
Oritavancin—Urticaria—Estradiol—prostate cancer	0.00109	0.00109	CcSEcCtD
Oritavancin—Immune system disorder—Capecitabine—prostate cancer	0.00109	0.00109	CcSEcCtD
Oritavancin—Mediastinal disorder—Capecitabine—prostate cancer	0.00109	0.00109	CcSEcCtD
Oritavancin—Headache—Goserelin—prostate cancer	0.00109	0.00109	CcSEcCtD
Oritavancin—Malnutrition—Docetaxel—prostate cancer	0.00108	0.00108	CcSEcCtD
Oritavancin—Rash—Conjugated Estrogens—prostate cancer	0.00108	0.00108	CcSEcCtD
Oritavancin—Dermatitis—Conjugated Estrogens—prostate cancer	0.00108	0.00108	CcSEcCtD
Oritavancin—Headache—Conjugated Estrogens—prostate cancer	0.00108	0.00108	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Epirubicin—prostate cancer	0.00107	0.00107	CcSEcCtD
Oritavancin—Infection—Etoposide—prostate cancer	0.00106	0.00106	CcSEcCtD
Oritavancin—Connective tissue disorder—Prednisone—prostate cancer	0.00106	0.00106	CcSEcCtD
Oritavancin—Malnutrition—Capecitabine—prostate cancer	0.00105	0.00105	CcSEcCtD
Oritavancin—Tachycardia—Etoposide—prostate cancer	0.00104	0.00104	CcSEcCtD
Oritavancin—Eosinophilia—Epirubicin—prostate cancer	0.00104	0.00104	CcSEcCtD
Oritavancin—Skin disorder—Etoposide—prostate cancer	0.00103	0.00103	CcSEcCtD
Oritavancin—Nausea—Goserelin—prostate cancer	0.00103	0.00103	CcSEcCtD
Oritavancin—Nausea—Conjugated Estrogens—prostate cancer	0.00102	0.00102	CcSEcCtD
Oritavancin—Urticaria—Mitoxantrone—prostate cancer	0.00102	0.00102	CcSEcCtD
Oritavancin—Hypersensitivity—Estradiol—prostate cancer	0.00101	0.00101	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	0.00101	0.00101	CcSEcCtD
Oritavancin—Anaemia—Docetaxel—prostate cancer	0.001	0.001	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Doxorubicin—prostate cancer	0.000992	0.000992	CcSEcCtD
Oritavancin—Pruritus—Estradiol—prostate cancer	0.000973	0.000973	CcSEcCtD
Oritavancin—Anaemia—Capecitabine—prostate cancer	0.000971	0.000971	CcSEcCtD
Oritavancin—Immune system disorder—Prednisone—prostate cancer	0.000971	0.000971	CcSEcCtD
Oritavancin—Eosinophilia—Doxorubicin—prostate cancer	0.000962	0.000962	CcSEcCtD
Oritavancin—Hypersensitivity—Mitoxantrone—prostate cancer	0.000944	0.000944	CcSEcCtD
Oritavancin—Diarrhoea—Estradiol—prostate cancer	0.000941	0.000941	CcSEcCtD
Oritavancin—Infestation NOS—Epirubicin—prostate cancer	0.000936	0.000936	CcSEcCtD
Oritavancin—Infestation—Epirubicin—prostate cancer	0.000936	0.000936	CcSEcCtD
Oritavancin—Malnutrition—Prednisone—prostate cancer	0.000936	0.000936	CcSEcCtD
Oritavancin—Myalgia—Docetaxel—prostate cancer	0.000924	0.000924	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Etoposide—prostate cancer	0.00092	0.00092	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000917	0.000917	CcSEcCtD
Oritavancin—Dizziness—Estradiol—prostate cancer	0.000909	0.000909	CcSEcCtD
Oritavancin—Myalgia—Capecitabine—prostate cancer	0.000894	0.000894	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000888	0.000888	CcSEcCtD
Oritavancin—Infection—Docetaxel—prostate cancer	0.00088	0.00088	CcSEcCtD
Oritavancin—Diarrhoea—Mitoxantrone—prostate cancer	0.000876	0.000876	CcSEcCtD
Oritavancin—Vomiting—Estradiol—prostate cancer	0.000874	0.000874	CcSEcCtD
Oritavancin—Nervous system disorder—Docetaxel—prostate cancer	0.000868	0.000868	CcSEcCtD
Oritavancin—Rash—Estradiol—prostate cancer	0.000867	0.000867	CcSEcCtD
Oritavancin—Infestation—Doxorubicin—prostate cancer	0.000866	0.000866	CcSEcCtD
Oritavancin—Infestation NOS—Doxorubicin—prostate cancer	0.000866	0.000866	CcSEcCtD
Oritavancin—Dermatitis—Estradiol—prostate cancer	0.000866	0.000866	CcSEcCtD
Oritavancin—Anaemia—Prednisone—prostate cancer	0.000865	0.000865	CcSEcCtD
Oritavancin—Tachycardia—Docetaxel—prostate cancer	0.000864	0.000864	CcSEcCtD
Oritavancin—Headache—Estradiol—prostate cancer	0.000861	0.000861	CcSEcCtD
Oritavancin—Skin disorder—Docetaxel—prostate cancer	0.00086	0.00086	CcSEcCtD
Oritavancin—Angioedema—Prednisone—prostate cancer	0.000855	0.000855	CcSEcCtD
Oritavancin—Infection—Capecitabine—prostate cancer	0.000852	0.000852	CcSEcCtD
Oritavancin—Urticaria—Etoposide—prostate cancer	0.000846	0.000846	CcSEcCtD
Oritavancin—Nervous system disorder—Capecitabine—prostate cancer	0.000841	0.000841	CcSEcCtD
Oritavancin—Tachycardia—Capecitabine—prostate cancer	0.000837	0.000837	CcSEcCtD
Oritavancin—Skin disorder—Capecitabine—prostate cancer	0.000833	0.000833	CcSEcCtD
Oritavancin—Oedema peripheral—Epirubicin—prostate cancer	0.000828	0.000828	CcSEcCtD
Oritavancin—Connective tissue disorder—Epirubicin—prostate cancer	0.000826	0.000826	CcSEcCtD
Oritavancin—Nausea—Estradiol—prostate cancer	0.000816	0.000816	CcSEcCtD
Oritavancin—Vomiting—Mitoxantrone—prostate cancer	0.000814	0.000814	CcSEcCtD
Oritavancin—Rash—Mitoxantrone—prostate cancer	0.000808	0.000808	CcSEcCtD
Oritavancin—Dermatitis—Mitoxantrone—prostate cancer	0.000807	0.000807	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000807	0.000807	CcSEcCtD
Oritavancin—Headache—Mitoxantrone—prostate cancer	0.000802	0.000802	CcSEcCtD
Oritavancin—Myalgia—Prednisone—prostate cancer	0.000797	0.000797	CcSEcCtD
Oritavancin—Erythema multiforme—Epirubicin—prostate cancer	0.000795	0.000795	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000791	0.000791	CcSEcCtD
Oritavancin—Hypersensitivity—Etoposide—prostate cancer	0.000785	0.000785	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000781	0.000781	CcSEcCtD
Oritavancin—Cardiac disorder—Epirubicin—prostate cancer	0.00078	0.00078	CcSEcCtD
Oritavancin—Oedema peripheral—Doxorubicin—prostate cancer	0.000766	0.000766	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000764	0.000764	CcSEcCtD
Oritavancin—Connective tissue disorder—Doxorubicin—prostate cancer	0.000764	0.000764	CcSEcCtD
Oritavancin—Nausea—Mitoxantrone—prostate cancer	0.000761	0.000761	CcSEcCtD
Oritavancin—Immune system disorder—Epirubicin—prostate cancer	0.000759	0.000759	CcSEcCtD
Oritavancin—Infection—Prednisone—prostate cancer	0.000759	0.000759	CcSEcCtD
Oritavancin—Mediastinal disorder—Epirubicin—prostate cancer	0.000758	0.000758	CcSEcCtD
Oritavancin—Pruritus—Etoposide—prostate cancer	0.000754	0.000754	CcSEcCtD
Oritavancin—Nervous system disorder—Prednisone—prostate cancer	0.000749	0.000749	CcSEcCtD
Oritavancin—Tachycardia—Prednisone—prostate cancer	0.000745	0.000745	CcSEcCtD
Oritavancin—Skin disorder—Prednisone—prostate cancer	0.000742	0.000742	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Capecitabine—prostate cancer	0.00074	0.00074	CcSEcCtD
Oritavancin—Erythema multiforme—Doxorubicin—prostate cancer	0.000735	0.000735	CcSEcCtD
Oritavancin—Malnutrition—Epirubicin—prostate cancer	0.000732	0.000732	CcSEcCtD
Oritavancin—Diarrhoea—Etoposide—prostate cancer	0.000729	0.000729	CcSEcCtD
Oritavancin—Cardiac disorder—Doxorubicin—prostate cancer	0.000722	0.000722	CcSEcCtD
Oritavancin—Dizziness—Etoposide—prostate cancer	0.000705	0.000705	CcSEcCtD
Oritavancin—Immune system disorder—Doxorubicin—prostate cancer	0.000703	0.000703	CcSEcCtD
Oritavancin—Mediastinal disorder—Doxorubicin—prostate cancer	0.000701	0.000701	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000696	0.000696	CcSEcCtD
Oritavancin—Urticaria—Capecitabine—prostate cancer	0.000681	0.000681	CcSEcCtD
Oritavancin—Vomiting—Etoposide—prostate cancer	0.000677	0.000677	CcSEcCtD
Oritavancin—Malnutrition—Doxorubicin—prostate cancer	0.000677	0.000677	CcSEcCtD
Oritavancin—Anaemia—Epirubicin—prostate cancer	0.000676	0.000676	CcSEcCtD
Oritavancin—Rash—Etoposide—prostate cancer	0.000672	0.000672	CcSEcCtD
Oritavancin—Dermatitis—Etoposide—prostate cancer	0.000671	0.000671	CcSEcCtD
Oritavancin—Headache—Etoposide—prostate cancer	0.000667	0.000667	CcSEcCtD
Oritavancin—Hypersensitivity—Docetaxel—prostate cancer	0.000652	0.000652	CcSEcCtD
Oritavancin—Nausea—Etoposide—prostate cancer	0.000633	0.000633	CcSEcCtD
Oritavancin—Hypersensitivity—Capecitabine—prostate cancer	0.000632	0.000632	CcSEcCtD
Oritavancin—Pruritus—Docetaxel—prostate cancer	0.000626	0.000626	CcSEcCtD
Oritavancin—Anaemia—Doxorubicin—prostate cancer	0.000626	0.000626	CcSEcCtD
Oritavancin—Myalgia—Epirubicin—prostate cancer	0.000623	0.000623	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000619	0.000619	CcSEcCtD
Oritavancin—Urticaria—Prednisone—prostate cancer	0.000607	0.000607	CcSEcCtD
Oritavancin—Pruritus—Capecitabine—prostate cancer	0.000606	0.000606	CcSEcCtD
Oritavancin—Diarrhoea—Docetaxel—prostate cancer	0.000606	0.000606	CcSEcCtD
Oritavancin—Infection—Epirubicin—prostate cancer	0.000593	0.000593	CcSEcCtD
Oritavancin—Diarrhoea—Capecitabine—prostate cancer	0.000587	0.000587	CcSEcCtD
Oritavancin—Nervous system disorder—Epirubicin—prostate cancer	0.000586	0.000586	CcSEcCtD
Oritavancin—Dizziness—Docetaxel—prostate cancer	0.000585	0.000585	CcSEcCtD
Oritavancin—Tachycardia—Epirubicin—prostate cancer	0.000583	0.000583	CcSEcCtD
Oritavancin—Skin disorder—Epirubicin—prostate cancer	0.00058	0.00058	CcSEcCtD
Oritavancin—Myalgia—Doxorubicin—prostate cancer	0.000576	0.000576	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000572	0.000572	CcSEcCtD
Oritavancin—Dizziness—Capecitabine—prostate cancer	0.000567	0.000567	CcSEcCtD
Oritavancin—Vomiting—Docetaxel—prostate cancer	0.000563	0.000563	CcSEcCtD
Oritavancin—Hypersensitivity—Prednisone—prostate cancer	0.000563	0.000563	CcSEcCtD
Oritavancin—Rash—Docetaxel—prostate cancer	0.000558	0.000558	CcSEcCtD
Oritavancin—Dermatitis—Docetaxel—prostate cancer	0.000558	0.000558	CcSEcCtD
Oritavancin—Headache—Docetaxel—prostate cancer	0.000555	0.000555	CcSEcCtD
Oritavancin—Infection—Doxorubicin—prostate cancer	0.000549	0.000549	CcSEcCtD
Oritavancin—Vomiting—Capecitabine—prostate cancer	0.000545	0.000545	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000544	0.000544	CcSEcCtD
Oritavancin—Nervous system disorder—Doxorubicin—prostate cancer	0.000542	0.000542	CcSEcCtD
Oritavancin—Rash—Capecitabine—prostate cancer	0.00054	0.00054	CcSEcCtD
Oritavancin—Pruritus—Prednisone—prostate cancer	0.00054	0.00054	CcSEcCtD
Oritavancin—Dermatitis—Capecitabine—prostate cancer	0.00054	0.00054	CcSEcCtD
Oritavancin—Tachycardia—Doxorubicin—prostate cancer	0.000539	0.000539	CcSEcCtD
Oritavancin—Headache—Capecitabine—prostate cancer	0.000537	0.000537	CcSEcCtD
Oritavancin—Skin disorder—Doxorubicin—prostate cancer	0.000537	0.000537	CcSEcCtD
Oritavancin—Nausea—Docetaxel—prostate cancer	0.000526	0.000526	CcSEcCtD
Oritavancin—Diarrhoea—Prednisone—prostate cancer	0.000522	0.000522	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000516	0.000516	CcSEcCtD
Oritavancin—Nausea—Capecitabine—prostate cancer	0.000509	0.000509	CcSEcCtD
Oritavancin—Dizziness—Prednisone—prostate cancer	0.000505	0.000505	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000503	0.000503	CcSEcCtD
Oritavancin—Vomiting—Prednisone—prostate cancer	0.000485	0.000485	CcSEcCtD
Oritavancin—Rash—Prednisone—prostate cancer	0.000481	0.000481	CcSEcCtD
Oritavancin—Dermatitis—Prednisone—prostate cancer	0.000481	0.000481	CcSEcCtD
Oritavancin—Headache—Prednisone—prostate cancer	0.000478	0.000478	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000477	0.000477	CcSEcCtD
Oritavancin—Urticaria—Epirubicin—prostate cancer	0.000474	0.000474	CcSEcCtD
Oritavancin—Nausea—Prednisone—prostate cancer	0.000454	0.000454	CcSEcCtD
Oritavancin—Hypersensitivity—Epirubicin—prostate cancer	0.00044	0.00044	CcSEcCtD
Oritavancin—Urticaria—Doxorubicin—prostate cancer	0.000439	0.000439	CcSEcCtD
Oritavancin—Pruritus—Epirubicin—prostate cancer	0.000423	0.000423	CcSEcCtD
Oritavancin—Diarrhoea—Epirubicin—prostate cancer	0.000409	0.000409	CcSEcCtD
Oritavancin—Hypersensitivity—Doxorubicin—prostate cancer	0.000407	0.000407	CcSEcCtD
Oritavancin—Dizziness—Epirubicin—prostate cancer	0.000395	0.000395	CcSEcCtD
Oritavancin—Pruritus—Doxorubicin—prostate cancer	0.000391	0.000391	CcSEcCtD
Oritavancin—Vomiting—Epirubicin—prostate cancer	0.00038	0.00038	CcSEcCtD
Oritavancin—Diarrhoea—Doxorubicin—prostate cancer	0.000378	0.000378	CcSEcCtD
Oritavancin—Rash—Epirubicin—prostate cancer	0.000377	0.000377	CcSEcCtD
Oritavancin—Dermatitis—Epirubicin—prostate cancer	0.000376	0.000376	CcSEcCtD
Oritavancin—Headache—Epirubicin—prostate cancer	0.000374	0.000374	CcSEcCtD
Oritavancin—Dizziness—Doxorubicin—prostate cancer	0.000365	0.000365	CcSEcCtD
Oritavancin—Nausea—Epirubicin—prostate cancer	0.000355	0.000355	CcSEcCtD
Oritavancin—Vomiting—Doxorubicin—prostate cancer	0.000351	0.000351	CcSEcCtD
Oritavancin—Rash—Doxorubicin—prostate cancer	0.000348	0.000348	CcSEcCtD
Oritavancin—Dermatitis—Doxorubicin—prostate cancer	0.000348	0.000348	CcSEcCtD
Oritavancin—Headache—Doxorubicin—prostate cancer	0.000346	0.000346	CcSEcCtD
Oritavancin—Nausea—Doxorubicin—prostate cancer	0.000328	0.000328	CcSEcCtD
